TAS Minutes 24th May 2022(641 KB) - TAS
Date added: 30th Jun 2022
Drug Name | Classification | Clinical Indication | Comments |
---|---|---|---|
3,4 DIAMINOPYRIDINE | Red | Lambert Eaton Myasthenic Syndrome |
Unlicensed |
3,4-Diaminopyridine | Red | Lambert Eaton Myasthenic Syndrome | |
5-AMINOLAEVULINIC ACID GEL (Ameluz®) | Do not prescribe | Actinic keratosis | |
ABACAVIR / LAMIVUDINE (Kivexa®) | Red | ||
ABACAVIR/DOLUTEGRAVIR/LAMIVUDINE (Triumeq®) | Red | HIV | |
ABATACEPT | Red | Rheumatoid arthritis |
In line with NICE TA 195 and NICE TA 280 and NICE TA715 |
ABATACEPT | Red | Juvenile idiopathic arthritis |
In line with NICE TA 373 |
ABATACEPT | Red | Refractory idiopathic inflammatory myopathies (adults and children aged 2 years and over) | |
ACITRETIN | Red | For psoriasis, Icthyosis, palmoplantar pustulosis and Dariers disease in males and postmenopausal women. |
Reviewed by TAS 22nd June 2021 |
ALISKIREN (UPDATED) | Orange | Existing patients with Hypertension | |
ALISKIREN (NEW) | Do not prescribe | New patients | |
AMANTADINE (NEW) | Yellow | Prolonged disorder of consciousness | |
ANAKINRA (Kineret®) | Red | Still’s disease and juvenile idiopathic arthritis |
In line with NICE TA685
|
ANAKINRA (Kineret®) | Red | Haemophagocytic Lymphohistiocytisis | |
BALOXAVIR MARBOXIL (Xofluza®) | Grey | Treatment and post exposure prophylaxis of influenza | |
BELIMUMAB | Red | For treating active autoantibody positive systemic lupus erythematosus |
In line with NICE TA752. Implementation date 15th March 2022 |
BEMIPARIN (Zibor ®) | Grey | Prevention of thromboembolic disease. Prevention of clotting. | |
BEVACIZUMAB | Red | Treatment of angiodysplasia in the background of von Willebrand's disease second line to thalidomide use. | |
BLEPHACLEAN WIPES | Do not prescribe | Blepharitis | |
BUPRENORPHINE IMPLANT (Sixmo ® (implant)) | Grey | Substitution treatment for opioid dependence in clinically stable patients. | |
CABOTEGRAVIR WITH RILPIVIRINE | Red | For treating HIV-1 |
In line with NICE TA757. Implementation date 5th April. |
CENOBAMATE | Red | Focal onset seizures in epilepsy | |
CHLORAL HYDRATE/CLORAL BETAINE | Red | Insomnia in children and adolescents |
Traffic light change following MHRA restrictions. Should not be stopped suddenly, so there will need to be some continuation in primary care in the short term. |
CHLORMETHINE GEL (Ledaga®) | Red | Mycosis fungoides-type T cell lymphomas |
In line with NICE TA720 |
COLISTIN | Red | Nebulised for Cystic fibrosis | |
CRIZANLIZUMAB | Red | Preventing sickle cell crises in sickle cell disease |
In line with NICE TA743 |
DAPAGLIFLOZIN | Do not prescribe | Type 1 diabetes |
New patients |
DAPAGLIFLOZIN | Yellow | With insulin for treating Type 1 diabetes, historic patients only |
Now unlicensed due to commercial reasons
|
DAPAGLIFLOZIN (Forxiga®) (NEW) | Green | CKD in adults |
In line with NICE TA775 See CKD pathway for more information
|
DAPSONE (NEW) | Red | Dermatology | |
DELAFLOXACIN MEGLUMINE (Quofenix®) (UPDATED) | Red | Acute bacterial skin and skin structure infections | |
DEOXYCHOLIC ACID (Belkyra ®) | Grey | Moderate to severe convexity or fullness associated with submental fat in adults when the presence of submental fat has an important psychological impact for the patient | |
DEXAMFETAMINE | Orange | Excessive sleepiness caused by narcolepsy | |
DIROXIMEL FUMERATE (Vumerity®) | Grey | Relapsing-remitting multiple sclerosis | |
DOXAZOSIN M/R TABLETS (UPDATED) | Do not prescribe | Hypertension | |
DUPILUMAB | Red | Severe asthma with type 2 inflammation |
In line with NICE TA751. Implementation date 8th March 2022 |
EMPAGLIFLOZIN | Yellow | Chronic heart failure with reduced ejection fraction. |
In line with NICE TA773 |
ERAVACYCLINE (Xerava®) | Grey | Complicated intra-abdominal infections in adults | |
ESKETAMINE HYDROCHLORIDE NASAL SPRAY (Spravato®) | Red | In combination with a SSRI or SNRI for adults with treatment-resistant Major Depressive Disorder |
Administration in specialist clinic only |
ESTRADIOL HEMIHYDRATE/NORETHISTERONE ACETATE/RELUGOLIX (Ryeqo ®) | Grey | Treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. | |
FAMOTIDINE (NEW) | Green | H2 antagonist | |
FENFLURAMINE HYDROCHLORIDE (Fintepla ®) | Grey | Treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines. | |
FINERENONE (Kerendia®) (NEW) | Grey | Treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. | |
FORMOTEROL/BUDESONIDE/GLYCOPYRRONIUM INHALER (Trixeo Aerospace®) (UPDATED) | Do not prescribe | Moderate to severe COPD |
Reviewed by the Respiratory Prescribing Group May 2022 |
FOSTEMSAVIR (Rukobia ®) | Red | HIV Infections | |
FreeStyle Libre® Sensor (UPDATED) | Green | Diabetes glucose monitoring for those included on the LLRAPC position statement. |
Eligibility as per LLRAPC freestyle libre documents. Initial six month trial. Continuation dependent on letter detailing improvement in the NHSE England parameters. There are now primary care and secondary care documents.
|
FREMANEZUMAB (Ajovy®) | Red | Prevention of migraine |
In line with NICE TA764 |
GALANTAMINE Gazylan XL ® | Yellow | Alzheimer's disease | |
GALANTAMINE LIQUID | Red | Alzheimer's disease |
Leicestershire Partnership Trust consultants only |
GLYCEROL PHENYLBUTYRATE (Ravicti®) | Red | Chronic management of patients with urea cycle disorders (UCDs) | |
HYDROCORTISONE (Alkindi®)(Granules in capsules for opening) | Yellow | Adrenal insufficiency in paediatrics | |
ICOSAPENT ETHYL (Vazkepa ®) | Grey | Reduce the risk of cardiovascular events. | |
INCLISIRAN (Leqvio®) | Green | Treating primary hypercholesterolaemia or mixed dyslipidaemia. SECONDARY PREVENTION ONLY as per NICE TA733 |
For prescribers who feel competent to use this medication. In line with NICE TA733. The AAC Lipid management pathway gives further guidance on place in therapy and the AHSN have some inclisiran FAQS. Please see the Cardiovascular Guideline page |
INHALED DRY POWDER BUDESONIDE | Do not prescribe | Covid 19 treatment |
No longer recommended for Covid treatment outside of a trial in line with CAS 103185
|
LIOTHYRONINE | Red | Treatment of depression where other therapies have failed | |
LIOTHYRONINE (NEW) | Yellow | Hypothyroidism |
Monitoring will be undertaken by secondary care and patients remain open to secondary care. |
LIRAGLUTIDE (Saxenda®) | Red | Obesity in children aged over 12 years | |
LIRAGLUTIDE (Victoza®) | Yellow | Type 2 diabetes mellitus in children 10 years and over | |
LURASIDONE | Orange | schizophrenia in adults aged over 18 years |
For those who do not respond to or do not tolerate aripiprazole, or those who are not suitable for clozapine. |
LURASIDONE | Do not prescribe | Psychosis not associated with schizophrenia | |
LURASIDONE | Orange | Schizophrenia aged 13-17 years | |
LYUMJEV (NEW) | Green | Fast acting insulin for adults with diabetes mellitus | |
MELATONIN M/R 1mg and 5mg tablets (Slenyto®) | Yellow | Insomnia for children aged 2-18 years with Autism Spectrum Disorder and or Smith-Magenis syndrome | |
MEPACRINE (NEW) | Red | Refractory giardiasis | |
MEPOLIZUMAB (Nucala®) | Red | To treat severe eosinophilic asthma. |
In line with NICE TA 431 |
METHYLPHENIDATE | Orange | Excessive sleepiness caused by narcolepsy | |
METRELEPTIN (Myalepta ®) | Grey | Replacement therapy to treat the complications of leptin deficiency in lipodystrophy patients. | |
NEFOPAM | Green | Pain |
Non-formulary so use by exception only |
NINTEDANIB | Red | Fibrosing interstitial lung diseases |
In line with NICE TA747. Implementation date 17th February 2022. |
OCTREOTIDE | Red | Hight output stoma | |
ODEVIXIBAT SESQUIHYDRATE (Bylvay®) | Grey | Treatment of progressive familial intrahepatic cholestasis in patients aged 6 months or older. | |
ORITAVANCIN (Tenkasi®) (NEW) | Grey | Acute bacterial skin and skin structure infections | |
PALFORZIA | Red | Treating peanut allergy in children and young people. |
In line with NICE TA769 Implementation date 2nd May 2022 |
PEGCETACOPLAN | Do not prescribe | Paroxysmal nocturnal haemoglobinuria (PMH) |
Recommended by NICE TA788 but all prescribing is via the national PMH centre |
PERINDOPRIL ARGINE (UPDATED) | Do not prescribe | Hypertension | |
PITOLISANT | Do not prescribe | Excessive daytime sleepiness caused by obstructive sleep apnoea |
Not recommended by NICE TA776 |
PONESIMOD (Ponvory®) | Red | Relapsing forms of multiple sclerosis with active disease. |
In line with NICE TA767 Implementation date 2nd May 2022 |
RISDIPLAM | Do not prescribe | Spinal Muscular Atrophy |
Approved centres only. LLR is currently not an approved centre. |
RITUXIMAB | Do not prescribe | IgM paraproteinaemic demyelinating peripheral neuropathy in adults |
Approved centres only. LLR is currently not an approved centre. |
RIVAROXABAN | Yellow | ACS |
In line with NICE TA335 |
RIVAROXABAN (Xarelto®) | Yellow | Treatment of VTE in paediatric patients | |
ROXADUSTAT (Evrenzo ®) | Grey | Symptomatic anaemia associated with chronic kidney disease (CKD) in adults | |
RUPATADINE | Red | Urticaria in paediatrics | |
SALMETEROL / FLUTICASONE INHALATION POWDER (Seffalair Spiromax ®) | Grey | Asthma | |
SAPROPTERIN | Red | Hyperphenylalaninaemia in phenylketonuria |
In line with NICE TA729 |
SECUKINUMAB (Cosentyx®) | Red | Treating moderate to severe plaque psoriasis in children and young people |
In line with NICE TA734
|
SIROLIMUS Topical | Red | Angiofibromas associated with tuberous sclerosis complex | |
SOLRIAMFETOL (Sunosi ®) | Do not prescribe | Sleepiness in patients treated with CPAP for obstructive sleep apnoea |
Not recommended by NICE for this indication |
STRONTIUM RANELATE (NEW) | Red | Severe postmenopausal osteoporosis to reduce the risk of vertebral & non-vertebral fractures in patients without established cardiovascular disease when other treatments are contraindicated | |
SUCRALFATE ENEMAS (NEW) | Red | Radiation proctitis | |
TIPRANAVIR | Do not prescribe | HIV infection |
Discontinued |
TOFACITINIB | Red | Juvenile idiopathic arthritis |
In line with NICE TA735 Implementation date 20th January 2022 |
TOLVAPTAN (Samsca®) | Red | Hyponatraemia secondary to SIADH in patients requiring cancer chemotherapy | |
UPADACITINIB (Rinvoq®) | Red | Active psoriatic arthritis after inadequate response to DMARDs |
Comments: In line with NICE TA768 |
UPADACITINIB (Rinvoq®) | Red | Moderate rheumatoid arthritis in adults |
In line with NICE TA744 Implementation date 10th February 2022 |
VELMANASE ALFA (Lamzede ®) | Grey | Enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha mannosidosis | |
VIGABATRIN | Yellow | Epilepsy |
Clarification of historical status |
Recent documents from LLR APC and TAS
Date added: 30th Jun 2022
Date added: 22nd Jun 2022
Uploaded June 22
Date added: 17th Jun 2022
Uploaded June 22
Date added: 17th Jun 2022
Uploaded June 22
Date added: 17th Jun 2022
Date added: 15th Jun 2022
Version 1 Uploaded June 2022
Date added: 15th Jun 2022
Date added: 15th Jun 2022
Date added: 15th Jun 2022
Date added: 15th Jun 2022
Date added: 15th Jun 2022
Uploaded June 2022
Date added: 15th Jun 2022
Version 1 Uploaded June 2022
Date added: 10th Jun 2022
Version 1 Uploaded June 2022
Date added: 10th Jun 2022
Version 1 Uploaded June 2022
Date added: 10th Jun 2022
Version 1 Uploaded June 2022
Date added: 10th Jun 2022
Version 1 Uploaded June 2022
Date added: 8th Jun 2022
Version number 5.2 uploaded June 22
Date added: 4th Aug 2020
Updated version Uploaded June 22
Date added: 2nd May 2019
Version 2.0 uploaded June 22
Date added: 9th Apr 2019
Version 3.0 uploaded June 2022
Date added: 4th Apr 2019
Version 3 uploaded June 2022
Date added: 4th Apr 2019
version 2 Uploaded June 2022
Date added: 3rd May 2017
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more